Evidence map›Paper›PMID 40204936›Full record

ArticleScientific reports2025

Platelet miRNAs as early biomarkers for progression of idiopathic REM sleep behavior disorder to a synucleinopathy.

Laura Arnaldo, Jorge Mena, Mònica Serradell, Carles Gaig, David Adamuz, Dolores Vilas, Daniela Samaniego, Lourdes Ispierto, Angelica Montini, Gerard Mayà and 4 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Laura ArnaldoDepartment of Neuroscience, Research Institute Germans Trias i Pujol, Badalona, Spain.ORCID http://orcid.org/0000-0003-1654-0573
Jorge MenaDepartment of Neuroscience, Research Institute Germans Trias i Pujol, Badalona, Spain.ORCID http://orcid.org/0009-0001-4524-205X
Mònica SerradellDepartment of Neurology, Sleep Unit, Hospital Clínic de Barcelona, IDIBAPS, CIBERNED, Barcelona, Spain.ORCID http://orcid.org/0000-0002-2954-3020
Carles GaigDepartment of Neurology, Sleep Unit, Hospital Clínic de Barcelona, IDIBAPS, CIBERNED, Barcelona, Spain.ORCID http://orcid.org/0000-0002-7113-8125
David AdamuzDepartment of Neuroscience, Research Institute Germans Trias i Pujol, Badalona, Spain.ORCID http://orcid.org/0009-0008-0326-5991
Dolores VilasUnit of Neurodegenerative diseases, Department of Neurology, University Hospital Germans Trias I Pujol and the Germans Trias I Pujol Research Institute (IGTP) Badalona, Barcelona, Spain.ORCID http://orcid.org/0000-0003-3084-053X
Daniela SamaniegoUnit of Neurodegenerative diseases, Department of Neurology, University Hospital Germans Trias I Pujol and the Germans Trias I Pujol Research Institute (IGTP) Badalona, Barcelona, Spain.ORCID http://orcid.org/0000-0001-8362-0747
Lourdes IspiertoUnit of Neurodegenerative diseases, Department of Neurology, University Hospital Germans Trias I Pujol and the Germans Trias I Pujol Research Institute (IGTP) Badalona, Barcelona, Spain.ORCID http://orcid.org/0000-0002-1837-9675
Angelica MontiniDepartment of Neurology, Sleep Unit, Hospital Clínic de Barcelona, IDIBAPS, CIBERNED, Barcelona, Spain.ORCID http://orcid.org/0000-0001-5625-8850
Gerard MayàDepartment of Neurology, Sleep Unit, Hospital Clínic de Barcelona, IDIBAPS, CIBERNED, Barcelona, Spain.ORCID http://orcid.org/0000-0002-5025-2615
Ramiro ÁlvarezUnit of Neurodegenerative diseases, Department of Neurology, University Hospital Germans Trias I Pujol and the Germans Trias I Pujol Research Institute (IGTP) Badalona, Barcelona, Spain.ORCID http://orcid.org/0000-0002-8053-7232
Pau Pastor *Department of Neuroscience, Research Institute Germans Trias i Pujol, Badalona, Spain. pastorpau@gmail.com.ORCID http://orcid.org/0000-0002-7493-8777
Alex Iranzo *Department of Neurology, Sleep Unit, Hospital Clínic de Barcelona, IDIBAPS, CIBERNED, Barcelona, Spain. airanzo@clinic.cat.ORCID http://orcid.org/0000-0002-5618-8271
Katrin Beyer *Department of Neuroscience, Research Institute Germans Trias i Pujol, Badalona, Spain. kbeyer@igtp.cat.ORCID http://orcid.org/0000-0001-8905-1514

Funding

Spain's Ministry of Science and Innovation PMP22/00100
6 · The paper itself

Abstract

Individuals diagnosed with isolated REM sleep behavior disorder (IRBD) have a high risk of developing Lewy body disorders (LBD), mainly Parkinson's disease (PD) or dementia with Lewy bodies (DLB). As we have previously identified seven platelet-derived miRNAs as potential biomarkers for DLB, in this pilot study we aimed to investigate whether specific expression changes of these miRNAs are also present in IRBD. RNA was obtained from platelets of individuals with IRBD (n = 29) and controls (n = 34), and miRNA levels were determined with a miRCURY LNA miRNA Custom PCR Panel. miRNA interactomes of deregulated miRNAs were determined, and mRNA quantification of miRNA target genes was carried out using real-time PCR and the ΔΔCt method. We found that the expression of hsa-miR- 139 - 5p (p = 0.010) and hsa-miR- 142 - 3p (p = 0.017) was diminished, while hsa-miR- 191 - 5p (p = 0.023) was increased in platelets of IRBD patients compared with controls. Interactome analysis of these miRNAs showed that hsa-miR- 142 - 3p regulates genes related to the structure and maintenance of the cytoskeleton. Of the 15 genes expressed in platelets, the expression of WASL, a gene involved in actin filament organization, was increased in platelets of IRBD patients. Additionally, WASL expression correlated inversely with hsa-miR- 142 - 3p expression. Since the interactomes of hsa-miR- 139 - 5p and hsa-miR- 191 - 5p play a role in several cancer types, their expression was not addressed. Changes in hsa-miR- 142 - 3p, hsa-miR- 139 - 5p, and hsa-miR- 191 - 5p expression were found in IRBD platelets and might represent early biomarkers for LBD involving cytoskeleton dysfunction. Increased expression of WASL could indicate that altered platelet activation occurs early during the development of LBD.

Indexed as

Blood PlateletsMicroRNAsREM Sleep Behavior DisorderSynucleinopathiesAgedAged, 80 and overBiomarkersCase-Control StudiesDisease ProgressionFemaleHumansLewy Body DiseaseMaleMiddle AgedParkinson DiseasePilot ProjectsBiomarkersMicroRNAsBiomarkersIsolated REM sleep behavior disorderLewy body disordersMiRNA expressionPlatelets

Identifiers

PMID40204936
PMCPMC11982324

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.